Stay updated with breaking news from Michel Delforge. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Idecabtagene vicleucel resulted in meaningful improvements in symptoms, functioning, overall health status, and health-related quality of life vs standard regimens in select patients with triple-class exposed relapsed/refractory multiple myeloma, according to updated data from the phase 3 KarMMa-3 trial.
The quality-of-life improvement with Abecma in patients with relapsed/refractory multiple myeloma was greater when compared with standard regimens.
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma (RRMM) from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from
Subgroup analysis of outcomes for patients with high-risk relapsed and refractory multiple myeloma from the pivotal Phase 3 KarMMa-3 trial accepted for oral presentation at EHA Analysis from... | May 11, 2023
First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of... | May 11, 2023